Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. - Wikidata - wikimedia - TriplyDB

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.

http://www.wikidata.org/entity/Q34646948

about

SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives Efficacy and safety of canagliflozin among patients with type 2 diabetes mellitus: A systematic review and meta-analysis Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus Management of diabetes in the elderly with canagliflozin: A newer hypoglycemic drug on the horizon Sodium glucose transporter protein 2 inhibitors: focusing on the kidney to treat type 2 diabetes Renal sodium glucose cotransporter 2 inhibitors as a novel therapeutic approach to treatment of type 2 diabetes: Clinical data and mechanism of action Update on the treatment of type 2 diabetes mellitus Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic Agents SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure New and emerging drugs and targets for type 2 diabetes: reviewing the evidence Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin Influence of Familial Renal Glycosuria Due to Mutations in the SLC5A2 Gene on Changes in Glucose Tolerance over Time Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis Pharmacologic Approaches to Weight Management: Recent Gains and Shortfalls in Combating Obesity.The role of kidney in glucose homeostasis--SGLT2 inhibitors, a new approach in diabetes treatment.Sodium-Glucose linked transporter 2 (SGLT2) inhibitors--fighting diabetes from a new perspective.Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group compar Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies Standard and Novel Treatment Options for Metabolic Syndrome and Diabetes Mellitus Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data.Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus.Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes.Emerging treatments in type 2 diabetes: focus on canagliflozin.A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor.Update on developments with SGLT2 inhibitors in the management of type 2 diabetes Canagliflozin: a novel treatment option for type 2 diabetes.Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes.Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes.Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options.Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes Place of sodium-glucose co-transporter type 2 inhibitors for treatment of type 2 diabetes Patient profiling in diabetes and role of canagliflozin.Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial

P2860

Q26746901-451C7341-B0A2-46DE-B3B5-2F13D097BD49 Q26773558-3777EAB8-178B-4C23-B0A5-4DD30CE23CDF Q26777529-7FD01E4A-B705-47A9-9456-6A4241252405 Q26827362-19ECDCAC-4BB8-40D3-9AB8-1C0739AA2FE2 Q26864336-2CE40420-3E39-4D36-B302-56C56F0A0825 Q27027105-A4F39693-BAEA-4DD2-88C9-B5DA1D798713 Q28073342-BA3F6D46-FFA0-49C4-BA92-6156318F1416 Q28074843-87952BE2-1402-41D3-B341-CC831E3513EC Q28076978-FEA0CC19-8CA0-4943-804F-5F3B82A0B225 Q28079134-C220EFE8-89DA-4B94-A115-B49D7A657B4B Q28080114-0AB5E014-A6E8-4E69-A81E-47A3F0A81742 Q28085516-4020D340-2563-48B9-A11D-116D04E9ADBD Q28250844-A1984157-220A-4201-82CB-7C60B5CD3772 Q28552106-CF0F03AB-0AE2-458B-B4B9-25DA5FCBB854 Q28553482-855014F9-E278-4BF5-AB6C-4DD408F03C6E Q30250304-EC57F8E6-1073-4216-A918-A97761433BBB Q30663494-7AE8A7B0-0EEF-4FCA-A106-612B4C734CEC Q30833760-7D6706F8-AC9E-4992-B12E-FA72F33B8040 Q33567077-FE4BF05B-4DA2-4261-AC34-C8276E23C00A Q33612741-2D71BD2F-1151-4E36-AFB4-128CB14ADA42 Q33613143-4E1AF82E-DA80-4EA4-876E-C63FA476FB4B Q33618721-5CA7E8EC-9CE7-4267-A469-5376B7E0D248 Q33625568-26F41E90-F533-4E8A-B9AE-D57123BD11A7 Q33696974-313E84D1-C3C8-486A-A251-6ED3009578D7 Q33759610-BC110A3D-F12A-48CE-9730-14A896291575 Q33781497-5C28AE06-EF75-4634-A669-497116E2948D Q33802278-C7215837-4B12-43F0-BBB4-C53620FE490B Q34105064-2B53F2AF-60D0-4C55-8F93-093FC10831C5 Q34109789-C62D97F7-D24A-4C36-8DC0-560931AD1D4F Q34161881-52ABBC19-6B54-4999-862E-B30567660653 Q34198692-429F734B-EDE4-4D3A-8065-FE81358D5D08 Q34388544-0A804974-3C83-4520-8503-25FB58CF0B31 Q34439528-37A6B237-88AE-41B4-BA82-CC44F8F0165D Q34457919-480F7B6A-C5D6-4245-9CF3-C99C487CCB36 Q34543009-838901F9-0D50-4AA8-A1ED-D6EC640D5873 Q34563587-BD25EFBA-C53B-4C1C-B154-CF3BC28FF685 Q34567005-A86F133B-C8E7-4E14-B9E8-E7FACE979EBA Q34699217-3B45E313-EC41-4CF9-87B3-D4ABC8E8E0A3 Q34729268-CAC1F86D-A3E6-447C-ADB5-D1AD6A79D44E Q34804900-EC61DFDF-111C-49E7-B1A4-20005BA82EA3

P2860

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise.

http://www.wikidata.org/entity/Q34646948

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Efficacy and safety of canagli ...... rolled with diet and exercise.

@ast

Efficacy and safety of canagli ...... rolled with diet and exercise.

@en

Efficacy and safety of canagli ...... rolled with diet and exercise.

@nl

type

label

Efficacy and safety of canagli ...... rolled with diet and exercise.

@ast

Efficacy and safety of canagli ...... rolled with diet and exercise.

@en

Efficacy and safety of canagli ...... rolled with diet and exercise.

@nl

prefLabel

Efficacy and safety of canagli ...... rolled with diet and exercise.

@ast

Efficacy and safety of canagli ...... rolled with diet and exercise.

@en

Efficacy and safety of canagli ...... rolled with diet and exercise.

@nl

P1433

Q34646948-C5A5A003-34C2-4106-96AC-43CD4116EBE9

P1476

Q34646948-EAF045C4-2AAF-47DF-894D-7C10F6ACFA94

P2093

Q34646948-0220E71F-4685-4623-B1AA-DCE448967F16

Q34646948-53CC899B-C753-4059-953A-E5D5F91078EC

Q34646948-598AE6E3-BB82-4E40-AF79-B8D32CE25CB9

Q34646948-954A6256-E072-46E5-B8AE-2D1EF0E80F2E

Q34646948-BCA8F62A-B1C7-4678-872C-21EC66327710

Q34646948-D7803D31-7B8C-4757-865A-0EEB481E59DC

Q34646948-D7CB21A3-0BB3-4812-80A5-332F50702560

Q34646948-FDF9D878-6887-4BB2-952C-5174708F8F8E

P2860

Q34646948-1EF5C3D3-4818-422C-99E7-508F9A34F842

Q34646948-27538E8F-1355-4D7B-A435-332EF1677390

Q34646948-2F4902E9-BCFF-4F23-BA1E-896C8339757B

Q34646948-337996CC-9CEF-4BA6-93EC-A5CE7C9B66E4

Q34646948-387D055C-862E-4D01-9BC3-728651337125

Q34646948-3D845AB1-454E-486E-80B9-76547FECB8CD

Q34646948-72D4BDA1-8B14-4A4C-81EE-2AEAB253658D

Q34646948-8D95CD98-87E1-4847-999E-25AE261554B9

Q34646948-9B8355B0-947E-4C70-8851-0688DA98880C

Q34646948-AB49F5B1-50D5-4E65-89C3-D07DC83332F2

P304

Q34646948-5D905039-4C0D-4AC8-9C83-3810FB9FD5B3

P31

Q34646948-0BB31F02-3E15-49E9-8A3C-5C725F1F854F

P356

Q34646948-9D45F162-BA51-4D57-A458-F494AFA6703C

P433

Q34646948-77CE5C03-F60A-4D2B-9A32-DEE795D342DF

P478

Q34646948-990F68BD-4C34-4FDA-BF4C-6B6E6F4B35F3

P577

Q34646948-F9C689DA-23EF-471A-A486-CD4E38DDAB76

P5875

Q34646948-FE046F58-D60A-4916-B370-84F47512F669

P698

Q34646948-C6C70137-2B7C-4182-A1E7-6AFAED647CB9

P921

Q34646948-29FF5508-0EB2-4266-AB98-35F36AD92A89

Q34646948-572DACD1-4FFC-4FA3-941A-A912EDC359EC

Q34646948-7244BE70-4D2E-4359-BF30-25AC6C4A6B39

P932

Q34646948-B39699DE-E522-4258-9B8B-74A2A5291B9F

P356

P1433

Diabetes, Obesity and Metabolism

P1476

Efficacy and safety of canagli ...... rolled with diet and exercise.

@en

P2093

C Tong

http://www.w3.org/2001/XMLSchema#string

G Meininger

http://www.w3.org/2001/XMLSchema#string

K Stenlöf

http://www.w3.org/2001/XMLSchema#string

K Usiskin

http://www.w3.org/2001/XMLSchema#string

K-A Kim

http://www.w3.org/2001/XMLSchema#string

M Alba

http://www.w3.org/2001/XMLSchema#string

W Canovatchel

http://www.w3.org/2001/XMLSchema#string

W T Cefalu

http://www.w3.org/2001/XMLSchema#string

P2860

Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.

Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study.

Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies: a statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the Ameri

The importance of beta-cell management in type 2 diabetes.

Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study.

Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus

P304

372-382

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/DOM.12054

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234030884

http://www.w3.org/2001/XMLSchema#string

P698

23279307

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

canagliflozin hemihydrate

P932

3593184

http://www.w3.org/2001/XMLSchema#string